

1/9




Fig.1. Location of topographical epitopes on CD30 molecule

BEST AVAILABLE COPY

10/516766

2/9

Fig 2a. Amino acid sequences of the variable regions of anti-CD30 MAbs

VH	SEQ ID NO:	FR1	CDR1	FR2		CDR2	FR3		CDR3	FR4
				1	2		3	4		
T6	2	QVQLKESGPGLYTPSOSLRLITCTVSGFSLIS	KYSIH	WVRQPPGPGLEWIG	MIW	--GVENTDYN SALKS	RLSISRDNSKSQS VFLKMNLSQSDDTAMTYCAR	KDLGLYGM	-----NY WGQGIS TTVSA	
T7	3	QVQLQQSGAELVYRPQSSVTLISKCKASGYFT	SYWMN	WVKQRPQPGQGLEWIG	QIYP	--GDDDTINYNGKFKG	IATLTADKSSTAYMQLSSLTSESDAVYFCAR	RETGRGAWF	-----TY WGQGTLLTVTVA	
T13	4	QVQLQQSGAELAKPGASVQNSIKCKASGYFT	TYWMH	WVKQRPQPGQGLEWIG	YINP	--STGYTDYNEKFKD	IATLTADKSSTAYMQLSSLTSESDAVYFCV	RGSYDGNPF	-----AY WGQGTLLVSA	
T14	5	EVQLVESGGGLYVPQGGSLIUSCGVSGFTFS	DYYMY	WVRQTPPEKRLENIA	SISS	--GGSYTYSSDSVKG	RLTISRDNTKANLYMQMSSILKSETDAVYFCV	GPGGVL	-----DY WGQGTLLTVSS	
T24	6	QVQLQOOGAELVYRPQASVKLSQLSKCKASGYSET	SYWID	WVKQRPQPGQGLEWIG	NIYP	--SNAYTNNQNOKFD	KATLTVDKSSTAYMQLSSPTSESDAVYFCV	VLDYFYAM	-----DY WGQGTSTVTVSS	
T25	7	QVTIYKESGPGLQPSQTLSLTCFSGFSLIN	TSGVGVG	WIRQPPGCKGLEWLA	HIV	--WDDDERTNPVLKs	RLTISCDTSSNQVFLKIANVDTADSATYFCV	SMTVAF	-----PY WGRGTLTVTVA	
HeF1-I	8	EVKLVYESGGGLVYQPQGGSLRLSCATSGFTFS	DYWMN	WVRQPPGKALEWIG	FIRNKANGTYTEFSASVWIG	RFTISRDQSILYQMNTRAEADSATYFCAR	DPPYGNPHYYAM	-----DY WGQGTSTVTVSS		
CL2	9	EVQLQKSGTELVKPGASVVLSQLCKASGYFT	SYWMH	WVKQRPQPGQGLEWIG	NINP	--SNGGTTNYNEKFKS	KATLTIDKSSTAYMQLSSLTSESDAVYFCAR	RTETAOAPSF	-----AY WGQGTLLTVTVA	
K1-4	10	QVKLQESCTELAKPGAVXMSICASGYFT	DYWMH	WVKQRPQPGQGLEWIG	YINP	--NTAYTDDYNQKFKD	KATLTADKSSTAYMQLRSLSLTSESDAVYFCAK	KTQTWTMGF	-----PF WGQGTLLTVTVA	
T420	11	QVQLQQSGAELAKPGASVMSCKASGYFT	SYWMH	WVKQRPQPGQGLEWIG	YINP	--STPDYTDYNEKFKD	KATLTADKSSTAYMQLSSLTSESDAVYFCAT	RHYGSSYGF	-----AY WGQGTLLTVTVA	
T427	12	QVQLQQGPGTTELVRPGASVVLSQLCKASGYFT	SYWMN	WVKQRPQPGQGLEWIG	MIHP	--SDSETRLNQKFKD	RATLTVDKSSTAYMQLSSPTSESDAVYFCAS	EMDYYFAM	-----DY WGQGTSTVTVSS	
T405	13	QVQLQQIGELVRPGASVVLSQLCKASGYFTN	NYWIN	WVKQRPQPGQGLEWIG	NIYP	--SDGSRSYNQNOKFD	KATLTVDKPSSTAYMQLSSPTSESDAVYFCV	GS	-----X WGQGTLLVTVSA	
T105	14	QVTIYKESGPGLQPSQTLSLTCFSGFSLIS	TSGMGVS	WIRQPSGKOLEWLA	HIY	--WDDDKRYNPKSLS	RLTISKDTSNNQVFLKITSYTDATATYFCAR	RADGLYFYL	-----DV WGAGTIVTVSS	
T201	38	QVQLKESGPGLVAPQSQTLSLTCFSGFSLI	DYGVS	WVRQPPGKGLEWIG	MIW	--GDGNTDYNGLKS	RLSISKDNSKSQVFLKVNLSQTDTARYFCAR	PSTGTLF	-----AY WGQGTLLVTVSA	
T408	40	QVQLQQGPQGAELVVRPGASVVLSQLCKASGYFT	SYWIN	WTKQRPQPGQGLEWIG	NIYP	--SDSYNSYNQKFKD	KATLTVDKSSTAYMQLSSPTSESDAVYFCV	GS	-----X WGQGTLLVTVSA	

10/516766

3/9

Fig 2b. Amino acid sequences of the variable regions of anti-CD30 MAbs

V _L	SEQ ID NO.	FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4
T6	15	DIVMTQSQKFMSTSVDGRVSVTC	KASQ-----NVNTNVA	WYQQKPGQSPKALFY	SASYRYS GVPDRFIGSGSGTDFSLNIVSQEDLAEYFC	QQYNTRY-----	-----	-----
T7	16	DIVLTQSPASLAISLGQRATISC	RASESLEY-YGTTIMQ	WYQQKPGQSPKLLIY	AASNEVS GVPARFSGSGSGTDFSLNIVHPVEEDDAMYFC	HOSRKVP-----ST	FGGGTKLEIKRAD	
T13	17	DIVMTQSHKFNMSTSVDGRVYTIC	KASQ-----DVSTAVA	WYQQKPGQSPKLLIY	WASTRHT GVPDRFTGSGSGTDTYLTLISVQVEDLALYYC	QQHYSTP-----FT	FGSGTKLEIKRA	
T14-A	18	DIVMTQTPLSLPVLGQDASIC	RSSQNLIHS-NGNAYLQ	WYLQKPGQSPKLLIY	KVSNRFS GVPDRFGSGSGSGTDFALK1IRVEAEDLGVYFC	SQTHVP-----YT	FGGGTKLEIKRAD	
T14-B	19	DIVLTQSPASLAISLGQRATISC	RASESLEY-YGTTIMQ	WYQQKPGQSPKLLIY	AASNEVS GVPARFSGSGSGTDFSLNIVHPVEEDDAMYFC	HOSRKVP-----ST	FGGGTKLEIKRAD	
T21	20	DIQMNQSPSSLASLGDTTITC	HASQ-----NINNWLT	WYQQKPGQNPQLLIIY	KASNLIH GVPSRFGSGSGSGTGFTLTISLQPEDIAIYYC	QQGSQYP-----LT	FGAGTKLEIKRA	
T24	21	DIQMTQTSSLASLGDTTISC	RASQ-----DISNTLN	WYQQKPGDGTVKLLIY	YTSRLHS GVPSRFGSGSGSGTDSLTISNLQEEDIATYFC	QQVNTP-----RT	FGGGTKLEIKRA	
T25	22	DIVMSQSPSSLASLVGEKFTNC	KSSQSLIYSSNQKNFLA	WYQQKPGQSPKLLIY	WASTRES GVPARFSGSGSGTDFTLNIVPEEEEDASTYTC	QOHYRYP-----WT	FGGGTKLEIKRAR	
HepB-I	23	DIVLTQSPASLAISLGQRATISC	RASKVSA--SGNTYMH	WYQQKAGQSPKLLIY	LAASNLS GVPDRFTGSGSGSGTDFTLTISVQEDLAEYFC	QHSGELP-----FT	FGSGTKLEIKRA	
C12	24	DIVMTQSHKFNMSTSVDGRVSVTC	KASQ-----NVNTNVA	WYQQKPGQSPKALIY	SASYRYS GVPDRFTGSGSGSGTDFTLTISVQEDLAEYFC	QQYNISYP-----FT	FGSGTKLEIK	
K1-4	25	DIVLTQSHKSAMSVGERTLSC	KASE-----NVDFEVNS	WYQQKPGQSPKALIY	GASNRLHS GVPDRFIGSGSGSGRDFLTISVQEDLADYHC	QONTRYP-----LT	FGAGTKLEIK	
T120	26	DIVMTQSHKFNMSTSVDGRVSVTC	KASQ-----DVSTAVA	WYQQKPGQSPKLLIY	WASTRHT GVPDRFTGSGSGTDYSLTISVQEDLAVYYC	QOHYRTP-----FT	FGSGTKLEIKR	
T427	27	DIVLTQSPSTSALISLGQRATISC	RASESTDVS-YGNSPFH	WFQQQKPGQSPKLLIY	RASNLES GIPARFSGSGSGMTDFTLTINPVEADDVATYC	QOSNEDP-----RT	FGGGTKLEIKR	
T405	28	DIVMTQTPLTLSVTIGPASLSC	KSSQSLSDS-DGKTYLN	WLLQRPQSPKPLIY	LVSKLDS GVPDRFTGSGSGSGTDFTLKISERVEAEDLGVYTC	WQGAHFP-----RT	FGGGTKLEIKR	
T105	29	DIVMTQSHKFNMSTSVDGRVSVTC	KASQ-----NVNTNVA	WYQQKPGQSPPEALIY	SASYRYS GVPDRFTGSGSGTDFTLTISVQEDLAEYFC	QQYNISYP-----LT	FGSGTKLEIKR	
T201	39	EIVLTQSPPTMASPGERITTC	SASSG----ISSIYLH	WYQQKPGFSPKLLIY	RTSNLAS GVPFRFGSGSGSGTDSLTIIGMEADEVATYTC	QQGSIIP-----LT	FGAGTKLEIKRA	
T408	41	DIVMTQTPPLTLSVTIGPASLSC	KSSQSLSDS-DGKTYLN	WLLQRPQSPKPLIY	LVSKLDS GVPDRFTGSGSGTDFTLKISRVEAEDLGVYTC	WQGAHFP-----RT	FGGGTKLEIKRA	





Fig. 3


BEST AVAILABLE COPY

5/9

FIG. 4



6/9



CDC of anti-CD30 antibody in the absence of secondary antibody (15-h postincubation)

Fig. 6A Karpas299 (CD30 positive)





Fig. 6B L540 (CD30 positive)



8/9

Fig. 7B





Fig. 7A



BEST AVAILABLE COPY

9/9

Fig. 8A




Fig. 8B





Fig. 8C



BEST AVAILABLE COPY